The use of sensitive radionuclide molecular imaging may permit repetitive noninvasive assessment of HER2 expression in breast cancer metastases, addressing the issue of spatial and temporal heterogeneity of HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.